GSK / Scynexis: A Disappointing Q1 Earnings And Cooling GSK Catalyst - We Maintain Neutral Rating

GSK PLC (LSE:GSK, NYSE:GSK)'s seemingly positive earnings release on Wednesday has been labelled as just that by Stifel analysts, who were left mullin more_horizontal

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on more_horizontal

GSK PLC (LSE:GSK, NYSE:GSK) has received mixed reactions from City analysts despite an objectively strong third-quarter performance and raised financi more_horizontal

GSK (GSK) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $ more_horizontal

High demand for the vaccine pulled in around $850 million during the third quarter—reportedly double what analysts were expecting—and GSK said ann more_horizontal

GSK PLC (LSE:GSK, NYSE:GSK) said a strong third quarter performance has driven a further upgrade to full-year guidance boosted by demand for its respi more_horizontal

GSK raised its full-year profit and sales forecasts on Wednesday for the second time this year, betting on the strong launch of its respiratory syncyt more_horizontal

The company will for the first time report sales of Arexvy, its new RSV vaccine that launched this fall. more_horizontal